Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ginkgo Bioworks Holdings's Revenue for the
three
months ended in Jun. 2026 was $20.2 Mil. Ginkgo Bioworks Holdings's average Accounts Receivable for the
three
months ended in Jun. 2026 was $16.4 Mil.
Hence, Ginkgo Bioworks Holdings's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.23.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Ginkgo Bioworks Holdings Receivables Turnover Related Terms
Ginkgo Bioworks Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Ginkgo Bioworks Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DNA vs RZLT, EIKN, ARTV: Receivables Turnover Comparison
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginkgo Bioworks Holdings (DNA) has a Receivables Turnover of 1.23 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ginkgo Bioworks Holdings and its competitors. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #399 out of 845 companies in the Biotechnology industry, placing it in the top 47.2%.
Is Ginkgo Bioworks Holdings' Receivables Turnover too high?
Ginkgo Bioworks Holdings' current Receivables Turnover is 1.23. The Biotechnology industry median Receivables Turnover is 5.22. Ginkgo Bioworks Holdings' value of 1.23 is 76.4% below this industry median. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #399 out of 845 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Receivables Turnover compare to RZLT and EIKN?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #399 out of 845 companies for Receivables Turnover. This puts Ginkgo Bioworks Holdings in the upper half of its industry. The industry median Receivables Turnover is 5.22. Ginkgo Bioworks Holdings' value of 1.23 is 76.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.22, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginkgo Bioworks Holdings's current Receivables Turnover of 1.23 is 76.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ginkgo Bioworks Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginkgo Bioworks Holdings's current Receivables Turnover is 1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (DNA) is currently considered Fairly Valued. The stock's GF Value™ is $5.96, compared to a current price of $6.53 — trading 9.6% above its estimated fair value. The current Receivables Turnover is 1.23 and 76.4% below the Biotechnology industry median of 5.22. Ginkgo Bioworks Holdings' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNA), the current Receivables Turnover is 1.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginkgo Bioworks Holdings (DNA) Overvalued in 2026?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued.
The current stock price of $6.53 is trading 9.6% above its estimated GF Value™ of $5.96.
GuruFocus considers Ginkgo Bioworks Holdings to be Fairly Valued.
Key valuation signals for DNA:
Receivables Turnover: 1.23
GF Value™: $5.96 vs. price of $6.53 (9.6% above fair value)
Industry Position: 76.4% below the Biotechnology median (#399 of 845)
No single metric tells the full story. See the DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
60GF Score
Get the complete analysis for DNA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNA has been successfully added to your 
